BTZ is considered as an effective proteasome inhibitor, and BTZ-based therapy has been proved to be successfully applied to the clinical treatment of mantle cell lymphoma [21], diffuse large B-cell lymphoma [8], and plasmablastic lymphoma [9]. The gene discussed is CASC3; the disease is mantle cell lymphoma.